Gadolinium-enhanced MRI of the abnormal prostate

Area of Science:

• Radiology
• Oncology
• Urology

Background:

• Prostate MRI is crucial for diagnosing and staging prostate cancer.
• Gadolinium-based contrast agents are commonly used in MRI, but their utility in abnormal prostate imaging requires further investigation.

Purpose of the Study:

• To evaluate the effectiveness of a low osmolar gadolinium-based contrast agent in MRI of the abnormal prostate.
• To compare contrast-enhanced MRI with T2-weighted fast-spin echo (FSE) imaging for detecting prostate cancer and differentiating it from benign prostatic hyperplasia (BPH).

Main Methods:

• A prospective study involving eight patients (six with prostate cancer, two with BPH) undergoing prostatectomy.
• Preoperative MRI was performed on a 1.5 T system using a pelvic coil array, with and without Gadodiamide (0.3 mmol/kg).
• T2-weighted FSE imaging was acquired in the same planes as contrast-enhanced scans, followed by detailed pathologic correlation.

Main Results:

• Both BPH and prostate cancer demonstrated enhancement after intravenous contrast administration.
• Enhancement patterns were similar between BPH and cancer, although BPH exhibited more heterogeneous enhancement.
• Contrast-enhanced MRI did not offer advantages over T2-weighted FSE imaging in detecting cancer, differentiating tissue types, or assessing extra-prostatic spread.

Conclusions:

• Low osmolar gadolinium-based contrast agents do not enhance the diagnostic performance of prostate MRI for detecting or characterizing prostate cancer.
• T2-weighted FSE imaging remains a valuable tool for evaluating the abnormal prostate, comparable to contrast-enhanced techniques in this study.